S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD

S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD
Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc
Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc
Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD
Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD
Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD
Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD
Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD
Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD
Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD
Update on Arlo-Cel, a GPRC5D CAR-T, in RRMM | Ciara Freeman, MD, PhD
AI Using Multimodal Datasets to Predict Response to CAR-T Treatment | Ciara Freeman, MD, PhD
AI Using Multimodal Datasets to Predict Response to CAR-T Treatment | Ciara Freeman, MD, PhD
Prophylactic Tocilizumab to Prevent CRS During Bispecific Step-up Dosing | Astrid Torpe, MD
Prophylactic Tocilizumab to Prevent CRS During Bispecific Step-up Dosing | Astrid Torpe, MD
MajesTEC-3 Late-Breaking Trial Results | Luciano Costa, MD
MajesTEC-3 Late-Breaking Trial Results | Luciano Costa, MD
Promising Therapy for Hard-to-treat DLBCL: Epcoritamab + GemOx #DLBCL | Joshua Brody, MD
Promising Therapy for Hard-to-treat DLBCL: Epcoritamab + GemOx #DLBCL | Joshua Brody, MD